According to DRG epidemiology, more than 30 million people in the United States experience migraines, and more than 10% of migraineurs have chronic migraine (CM). Migraine prophylaxis is a core treatment approach for high-frequency episodic and CM patients to reduce migraine frequency, severity, and duration. Current drug treatment primarily includes a mix of off-label and approved drugs from a range of drug classes, including antiepileptic drugs, beta blockers, antidepressants, AbbVie / Allergan’s Botox, and multiple anti-CGRP monoclonal antibodies (MAbs), the first migraine-specific preventive brands. Prophylactic treatment is evolving as the number of agents from which to choose increases. With new oral CGRP receptor antagonists (Biohaven’s Nurtec ODT, AbbVie / Allergan’s atogepant) poised to enter the prophylactic segment, understanding patient pathways and the drivers of treatment decision-making are key for new players bringing novel brands to this large, underserved, and mostly generic market.
QUESTIONS ANSWERED
What patient share do oral standards of care and invasive brands garner overall and by line of therapy in migraine patients initiating treatment?
What are the drivers and constraints influencing physicians’ treatment decisions for migraine prophylaxis in the United States?
What role do Botox and the anti-CGRP MAbs play in the evolving treatment algorithm? Which MAb garners the most use and why?
What percentage of migraine patients are treated with monotherapy versus combination therapy? How long are migraineurs treated with prophylaxis?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Current Treatment Physician Insights Migraine Prophylaxis US April 2021
Meher Baba Kumar Nakka
Meher Baba Kumar Nakka, M.S.(Pharm.), is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this capacity, he works on a range of neurological indications, such as pain and migraine, and neurodegenerative disorders, such as Alzheimer’s disease. He holds a bachelor’s degree in pharmacy from Jawaharlal Nehru Technological University in Hyderabad and a master’s degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research in Mohali.
